P171 Efficacy and safety of upadacitinib in patients with active PsA and inadequate response to biologic DMARDs (SELECT-PsA-2): a double-blind, randomised controlled Phase III trial

被引：0
|
作者：
Genovese, Mark C. [1 ]
Lertratanakul, Apinya [2 ]
Anderson, Jaclyn [2 ]
Papp, Kim [3 ]
Tillett, William [4 ]
van den Bosch, Filip [5 ]
Tsuji, Shigeyoshi [6 ]
Dokoupilova, Eva [7 ]
Keiserman, Mauro [8 ]
Wang, Xin [2 ]
Zhong, Sheng [2 ]
Zueger, Patrick [2 ]
Pangan, Aileen [2 ]
Mease, Philip [9 ,10 ]
机构：
[1] Stanford Univ, Sch Med, Dept Immunol & Rheumatol, Palo Alto, CA USA
[2] AbbVie Inc, Med, N Chicago, IL USA
[3] Papp Clin Res & Prob Med Res, Waterloo, ON, Canada
[4] Royal Natl Hosp Rheumat Dis, Rheumatol, Bath, Avon, England
[5] Ghent Univ Hosp, Dept Internal Med, Ghent, Belgium
[6] Osaka Minami Med Ctr, Dept Orthopaed Rheumatol, Osaka, Japan
[7] Uherske Hradiste & Univ Vet & Pharmaceut Sci, Med Plus, Brno, Czech Republic
[8] Pontificia Univ Catolica, Sch Med, Porto Alegre, RS, Brazil
[9] Swedish Med Ctr, Dept Rheumatol, Seattle, WA USA
[10] Univ Washington, Seattle, WA 98195 USA
来源：
RHEUMATOLOGY | 2021年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGICS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY
    Mease, P. J.
    Setty, A.
    Papp, K.
    Van den Bosch, F.
    Tsuji, S.
    Keiserman, M.
    Carter, K.
    Mccaskill, R.
    Mcdearmon-Blondell, E.
    Wung, P.
    Tillett, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1136 - 1137
  • [22] Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
    Burmester, Gerd R.
    Kremer, Joel M.
    Van den Bosch, Filip
    Kivitz, Alan
    Bessette, Louis
    Li, Yihan
    Zhou, Yijie
    Othman, Ahmed A.
    Pangan, Aileen L.
    Camp, Heidi S.
    LANCET, 2018, 391 (10139): : 2503 - 2512
  • [23] Upadacitinib As Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
    Smolen, Josef S.
    Cohen, Stanley
    Emery, Paul
    Rigby, William F. C.
    Tanaka, Yoshiya
    Zhang, Ying
    Friedman, Alan
    Othman, Ahmed A.
    Camp, Heidi S.
    Pangan, Aileen L.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [24] UPADACITINIB AS MONOTHERAPY: A PHASE 3 RANDOMIZED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE
    Smolen, J. S.
    Cohen, S.
    Emery, P.
    Rigby, W.
    Tanaka, Y.
    Zhang, Y.
    Friedman, A.
    Othman, A. A.
    Camp, H. S.
    Pangan, A. L.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S52 - S52
  • [25] Efficacy and Safety of Upadacitinib versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
    McInnes, Iain
    Anderson, Jaclyn K.
    Magrey, Marina
    Merola, Joseph
    Liu, Yi
    Kishimoto, Mitsumasa
    Jeka, Slawomir
    Tena, Cesar Pacheco
    Wang, Xin
    Chen, Liang
    Zueger, Patrick
    Pangan, Aileen
    Behrens, Frank
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [26] A randomised, double-blind, placebo-controlled phase III trial on the efficacy and safety of tocilizumab in patients with familial Mediterranean fever
    Koga, T.
    Sato, S.
    Hagimori, N.
    Yamamoto, H.
    Ishimura, M.
    Yasumi, T.
    Kirino, Y.
    Ikeda, K.
    Yachie, A.
    Migita, K.
    Kishida, D.
    Atsumi, T.
    Kawakami, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (08) : 1535 - 1542
  • [27] A PHASE 2B/3 RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF UPADACITINIB, A SELECTIVE JAK1 INHIBITOR, IN JAPANESE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS
    Tanaka, Y.
    Takeuchi, T.
    Yamaoka, K.
    Oribe, M.
    Kawano, M.
    Zhou, Y.
    Othman, A. A.
    Pangan, A. L.
    Kitamura, S.
    Matsuda, N.
    Meerwein, S.
    Kameda, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 991 - 992
  • [28] Efficacy and safety of Elagolix in endometriosis: Phase-III randomized double-blind active-controlled trial
    Gupta, N.
    Palve, T.
    Kamilya, G.
    Srivastava, S.
    Malathi, P.
    Bohir, S.
    Patel, J. S.
    Dash, M. K.
    Saigal, S.
    Savalia, K. P.
    Gupta, T.
    Chaudhary, D.
    Manohar, R.
    Shah, P.
    Bhat, V. V.
    Shetty, A.
    Saha, S.
    Quadros, R.
    Patil, D.
    Patel, P.
    Ghadge, P.
    Mane, A.
    Mehta, S.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2024, 131 : 3 - 3
  • [29] SAFETY AND EFFICACY OF FILGOTINIB IN JAPANESE PATIENTS ENROLLED IN A GLOBAL PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DMARDS
    Takeuchi, Tsutomu
    Matsubara, Tsukasa
    Atsumi, Tatsuya
    Amano, Koichi
    Ishiguro, Naoki
    Sugiyama, Eiji
    Yamaoka, Kunihiro
    Genovese, Mark C.
    Kalunian, Kenneth
    Walker, David
    Gottenberg, Jacques-Eric
    de Vlam, Kurt
    Mozaffarian, Neelufar
    Bartok, Beatrix
    Matzkies, Franziska
    Gao, Jie
    Guo, Ying
    Tasset, Chantal
    Sundy, John
    Tanaka, Yoshiya
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1686 - 1687
  • [30] A PHASE 3 RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF UPADACITINIB (ABT-494), A SELECTIVE JAK-1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS
    Burmester, G.
    Kremer, J.
    van den Bosch, F.
    Li, Y.
    Zhou, Y.
    Othman, A.
    Pangan, A.
    Camp, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 68 - 69
12345